Search
Gantenerumab
go.drugbank.com/drugs/DB12034Investigational[A244705, A244710, A244745] Gantenerumab is a fully human IgG1κ monoclonal antibody derived from the MorphoSys HuCAL®-Fab1 phage display library and subsequently optimized by _in vitro_ CDR cassette … Despite the clear association of Aβ aggregation with AD, treatments aimed at preventing Aβ aggregation or removing pre-existing Aβ plaques have shown little to no clinical benefit thus far and remain controversial
Levoketoconazole
go.drugbank.com/drugs/DB05667Approved[A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production. … Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying
Ketamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedIt was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332] … It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects.
Synonyms: 2-(o-chlorophenyl)-2-(methylamino)-cyclohexanoneCategories: N-Methylaspartate, agonists, N-Methylaspartate, antagonists & inhibitorsGuanadrel
go.drugbank.com/drugs/DB00226ApprovedGuanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.
Entacapone
go.drugbank.com/drugs/DB00494ApprovedInvestigationalWhen administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration … Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols.
Mixtures: LEVOCAENT-NX 100/25/200, LEVOCAENT-NX 100/25/200Synonyms: (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide, N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamideDasatinib
go.drugbank.com/drugs/DB01254ApprovedInvestigational[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. … [A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Synonyms: N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamideLumasiran
go.drugbank.com/drugs/DB15935ApprovedInvestigational[L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … [L23394] Prior to this approval, therapy consisted of symptomatic treatment such as hyperhydration, inhibitors of crystallization, [pyridoxine], and renal transplant.
Glycine
go.drugbank.com/drugs/DB00145ApprovedInvestigationalNutraceuticalVet approvedA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.
Mixtures: Vamin N, AMINOSTERIL N-HEPA 8%IPH 2101
go.drugbank.com/drugs/DB06049InvestigationalIPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
Darolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigational[A189063] Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. … The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.